GeoVax to Participate in Benzinga Biotech Small Cap Conference
via NewMediaWire – GeoVax Labs, Inc. (NasdaqCM: GOVX)
(“GeoVax” or the “Company”), a biotechnology company developing
vaccines and immunotherapies against infectious diseases and
cancers, announces that it will present at the Benzinga Biotech
Small Cap Conference to be held March 24-25, 2021.
On Wednesday, March 24, GeoVax’s Chief Scientific Officer, Mark
Newman, PhD, will participate in a panel discussion entitled,
Cancer Immunotherapies: Fighting Cancer with the Power of the
Immune System. The panel will discuss the advancements and
future of cancer immunotherapy, and Dr. Newman will share GeoVax’s
approach and perspective in this space.
On Thursday, March 25, GeoVax’s Chairman and CEO, David Dodd,
will present an overview of GeoVax’s immunotherapy and vaccine
research and development efforts, focusing on the Company’s ongoing
efforts to develop a COVID-19 vaccine addressing a range of
SARS-CoV-2 variants. Mr. Dodd will also discuss the Company’s
cancer immunotherapy programs.
Investors can view the presentation and the panel by registering
for the conference here and can also request a 1x1 meeting with Mr.
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines against infectious diseases and cancer
using a novel patented Modified Vaccinia Ankara-Virus Like Particle
(MVA-VLP) based vaccine platform. On this platform, MVA, a large
virus capable of carrying several vaccine antigens, expresses
proteins that assemble into VLP immunogens in the person receiving
the vaccine. The production of VLPs in the person being vaccinated
can mimic virus production in a natural infection, stimulating both
the humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP derived
vaccines can elicit durable immune responses in the host similar to
a live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused on preventive
vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever
viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as
therapeutic vaccines against multiple cancers. The Company has
designed a preventive HIV vaccine candidate to fight against the
subtype of HIV prevalent in the commercial markets of the Americas,
Western Europe, Japan, and Australia; human clinical trials for
this program are managed by the HIV Vaccine Trials Network (HVTN)
with the support of the National Institutes of Health (NIH).
GeoVax’s HIV vaccine is also part of two separate collaborative
efforts to apply its innovative gene therapy approach toward a
functional cure for HIV.